-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American Monday March 5, 5:14 pm ET
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc.'s (OTCBB: ACTC - News) ability to rescue vision in blind rats was noted in Scientific American's March 2007 issue as the lead story of its News Scan section. The full text of the article, which notes Advanced Cell's ability to "coax embryonic stem cells to turn into transplantable retinal pigment epithelial (RPE) tissue," is timely as it comes shortly after the company announced its collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU). ADVERTISEMENT
The article is available at the following link: http://www.sciam.com/article.cfm?chanID=sa006&articleID=C74A4206-E7F2- 99DF-3D2B8FC2C6B5D74C&colID=5 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists).
Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology commented, "We are pleased that Scientific American has taken note of Advanced Cell's progress. We are also excited about the many advantages offered by targeting the eye with RPE cells."
One of these advantages is the fact that the eye is immune-privileged, minimizing the use of immune suppressant drugs associated with other areas of the body that by definition reject foreign cells. The eye also requires only a small dosage of cells, reducing the amount necessary to be manufactured, which the company expects to be cost-effective in terms of trials. Another advantage is that the eye is a self-contained site, so the cells gravitate to the RPE layer. Since the site is contained, the cells are less likely to migrate beyond their target application, which could be the case if the site of application were in the blood stream. Additionally, the cells are easier to identify, because of their pigmentation, which is important for purity. Because the cells are easy to identify the risk of injecting foreign, or non-RPE cells into the eye is greatly reduced. Further, age-related diseases of the eye can potentially affect every human being, and ACTC is hopeful that its efforts will help serve a large and growing market.
Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer, Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------------------------------------------------------------------- Source: Advanced Cell Technology, Inc.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology's Ability to Rescue Vision in Blind Rats Noted in Scientific American
Mar 5, 2007 17:14:01 (ET)
ALAMEDA, Calif., Mar 05, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) ability to rescue vision in blind rats was noted in Scientific American's March 2007 issue as the lead story of its News Scan section. The full text of the article, which notes Advanced Cell's ability to "coax embryonic stem cells to turn into transplantable retinal pigment epithelial (RPE) tissue," is timely as it comes shortly after the company announced its collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU).
The article is available at the following link: http://www.sciam.com/article.cfm?chanID=sa006&articleID=C74A4206-E7F2- 99DF-3D2B8FC2C6B5D74C&colID=5 (Due to its length, this URL may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists).
Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology commented, "We are pleased that Scientific American has taken note of Advanced Cell's progress. We are also excited about the many advantages offered by targeting the eye with RPE cells."
One of these advantages is the fact that the eye is immune-privileged, minimizing the use of immune suppressant drugs associated with other areas of the body that by definition reject foreign cells. The eye also requires only a small dosage of cells, reducing the amount necessary to be manufactured, which the company expects to be cost-effective in terms of trials. Another advantage is that the eye is a self-contained site, so the cells gravitate to the RPE layer. Since the site is contained, the cells are less likely to migrate beyond their target application, which could be the case if the site of application were in the blood stream. Additionally, the cells are easier to identify, because of their pigmentation, which is important for purity. Because the cells are easy to identify the risk of injecting foreign, or non-RPE cells into the eye is greatly reduced. Further, age-related diseases of the eye can potentially affect every human being, and ACTC is hopeful that its efforts will help serve a large and growing market.
Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer, Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
WE JUST MAY GET A BOOST UP ON THIS NEWS! I LIKE THIS PART,Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer, Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
my studies of moneyology might pay off here!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell Technology's Ability to Rescue Vision in Blind RatsNoted in Scientific American
Mar 6, 2007 11:35:59 (ET)
ALAMEDA, CA, Mar 06, 2007 (MARKET WIRE via COMTEX) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) ability to rescue vision in blind rats was noted in Scientific American's March 2007 issue as the lead story of its News Scan section. The full text of the article, which notes Advanced Cell's ability to "coax embryonic stem cells to turn into transplantable retinal pigment epithelial (RPE) tissue," is timely as it comes shortly after the company announced its collaboration with the Casey Eye Institute at Oregon Health and Science University (OHSU).
Mr. William M. Caldwell, IV, Chairman and CEO of Advanced Cell Technology, commented, "We are pleased that Scientific American has taken note of Advanced Cell's progress. We are also excited about the many advantages offered by targeting the eye with RPE cells."
One of these advantages is the fact that the eye is immune-privileged, minimizing the use of immune suppressant drugs associated with other areas of the body that by definition reject foreign cells. The eye also requires only a small dosage of cells, reducing the amount necessary to be manufactured, which the company expects to be cost-effective in terms of trials. Another advantage is that the eye is a self-contained site, so the cells gravitate to the RPE layer. Since the site is contained, the cells are less likely to migrate beyond their target application, which could be the case if the site of application were in the blood stream. Additionally, the cells are easier to identify, because of their pigmentation, which is important for purity. Because the cells are easy to identify, the risk of injecting foreign or non-RPE cells into the eye is greatly reduced. Further, age-related diseases of the eye can potentially affect every human being, and ACTC is hopeful that its efforts will help serve a large and growing market.
Mr. Caldwell continued, "Our collaborations at OHSU will be important as we initiate toxicology and pharmacology studies to be managed by our newly appointed Chief Development Officer Dr. Pedro Huertas. These studies will be important milestones toward our anticipated filing of the company's first Investigational New Drug application (IND) with the FDA."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
Contact: The Investor Relations Group Investors: James Carbonara 212-825-3210
or
Media: Bill Douglass 212-825-3210
SOURCE: Advanced Cell Technology
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
pick a PR any PR..... give me all your RATS!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Haha, we need to add a new verse to the "three blind mice" song where they get healed by ACTC.
Posts: 252 | From: WestCoast | Registered: Oct 2006
| IP: Logged |
posted
All-Encompassing Explanation of Nature Puts Biology Into the Equation
Mar 8, 2007 13:02:12 (ET)
WORCESTER, Mass., Mar 08, 2007 (BUSINESS WIRE) -- Advanced Cell Technology's (ACTC, Trade ) Vice-President of Research & Scientific Development, Robert Lanza, M.D.'s, provocative new theory that time and space do not exist as physical realities independent of humans (and animals) has been published in a feature article "A New Theory of the Universe" in the Spring issue of "The American Scholar" (see Cover story http://www.theamericanscholar.org ), one of the nation's leading literary and intellectual publications. Dr. Lanza's article is the first cogent scientific theory that explains in simple, concrete terms, step-by-step, how the universe can be the way it is. Some of the greatest thinkers of our time have had their ideas published in The American Scholar, including Albert Einstein, Stephen Jay Gould, Bertrand Russell, Carl Sagan, John Updike, Robert Frost, Margaret Mead, and Saul Bellow, among others.
Dr. Lanza's new theory presents a shift in worldview with the perspective that life creates the universe instead of the other way around. This theory places biology above the other sciences in an attempt to solve one of nature's biggest puzzles, the theory of everything that other disciplines have been pursuing for the last century. Thousands of articles and books have danced around the desire to toss off the current mechanical worldview that has dominated Western culture for hundreds of years. While some imply that time and space may not in fact exist, Dr. Lanza's article diagrams for the first time, such a universe.
"It's a masterpiece," said Michael Lysaght, Professor of Medical Science at Brown University and Director of Brown's Center for Biomedical Engineering. "It's truly a magnificent essay. Bob Lanza is to be congratulated for a fresh and highly erudite look at the question of how perception and consciousness shape reality and common experience. His monograph combines a deep understanding and broad insight into 20th century physics and modern biological science."
"It is indeed stimulating and brings biology into the whole," said Nobel Laureate E. Donnall Thomas. "Any short statement does not do justice to such a scholarly work. Almost every society of mankind has explained the mystery of our surroundings and being by invoking a god or group of gods. Scientists work to acquire objective answers from the infinity of space or the inner machinery of the atom. Lanza proposes a biocentrist theory which ascribes the answer to the observer rather than the observed. The work is a scholarly consideration of science and philosophy that brings biology into the central role in unifying the whole."
"It is genuinely an exciting piece of work," said Ronald Green Ph.D., a well-known religious studies scholar and Eunice and Julian Cohen Professor for the Study of Ethics and Human Values at Dartmouth College. "The idea that consciousness creates reality has quantum support, and also coheres with some of the things biology and neuroscience are telling us about the structures of our being. Put in a larger context, it exhibits a dramatic new Copernican reversal. Just as we now know that the sun doesn't really move but we do (we are the active agents), this new theory suggests that we are the entities that give meaning to the particular configuration of all possible outcomes we call reality."
Anthony Atala, the W.H. Boyce Professor and Director of the Wake Forest University Institute for Regenerative Medicine says "Robert Lanza, a world renowned scientist who has spanned many fields from drug delivery to stem cells to preventing animal extinction, and clearly one of the most brilliant minds of our times, has done it again. 'A New Theory of the Universe' takes into account all the knowledge we have gained over the last few centuries, and correlates them to our own beings, placing in perspective our biologic limitations that have impeded our understanding of greater truths surrounding our existence and the universe around us. This new theory is certain to revolutionize our concepts of the laws of nature for centuries to come."
"As an astrophysicist," said David Thompson of NASA's Goddard Space Flight Center, "I focus my attention on objects that are very large and very far away, ignoring the whole issue of consciousness as a critical part of the Universe. Reading Robert Lanza's work is a wake-up call to all of us that even on the grandest scale we still depend on our minds to experience reality. Issues of "quantum weirdness" do have a place in the macroscopic world. Time and space do depend on perception. We can go about our daily lives with a better awareness of an underlying biological component, thanks to Dr. Lanza."
"I want to congratulate Dr. Lanza on this massive contribution to scientific thought," said William M. Caldwell, IV, Chairman and CEO of ACTC. "Putting aside the cogent and vibrant writing style, this 'new theory' is an achievement that will stimulate a whole new dimension for scientific debate and discourse. Whether stem cell research or biophysics, ACT scientists are encouraged to think outside of the box. Creative thinking is essential if we are to solve successfully the complex scientific challenges that lie ahead of us."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company visit www.advancedcell.com
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
"provocative new theory that time and space do not exist as physical realities independent of humans"
I can't get past this point ~ everything starts shaking ~ space time continuum or something...
lol
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
Press Release Source: Advanced Cell Technology, Inc.
Advanced Cell Technology Executives to Discuss ``The Business of Stem Cells'' and Participate in ``Conversations with Experts'' at The Stem Cell Meeting Hosted by Burrill and Company at UCSF Monday March 12, 9:07 am ET
ALAMEDA, Calif.--(BUSINESS WIRE)--Advanced Cell Technology, Inc.'s (OTCBB: ACTC - News) William M. Caldwell, IV, Chairman and CEO, will discuss "The Business of Stem Cells" at the Stem Cell Meeting, hosted by Burrill and Company at the University of California San Francisco (UCSF), today March 12 2007 at 10:00 AM PT. Also today, Michael West Ph.D., President and Chief Scientific Officer of Advanced Cell will participate as a stem cell expert during the "Conversations with Experts Roundtable Luncheon" at 12:00 PM PT. The conference will be held at the Mission Bay Conference Center at UCSF and will run from March 12-13, 2007.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
I WAS ONE DAY OFF- Advanced Cell Technology hESC lines to be used in CIRM-Funded Study To Test Development of New Therapies For Heart Disease
Mar 20, 2007 08:33:28 (ET)
ALAMEDA, Calif., Mar 20, 2007 (BUSINESS WIRE) -- Preclinical studies using hESCs derived from Advanced Cell Technology, Inc.'s (ACTC, Trade ) proprietary ACTcellerate technology (a means of accelerating the discovery of products from hESC) will be used as part of a study to determine if hESCs are safe and effective in animal models for heart attacks and heart failure.
The studies will be funded under a $2.52 million grant awarded to University of California, San Francisco (UCSF) scientist Randall Lee, M.D, Ph.D., Associate Professor of Medicine, from the California Institute for Regenerative Medicine. The grant is for four years of study. CIRM, the governing body of Proposition 71, manages the $3 billion California initiative.
Michael D. West, Ph.D., President and Chief Scientific Officer of ACTC, said, "We are encouraged that CIRM's funding will potentially speed therapies to the bedside for the 400,000 Americans who die suddenly from new or recurring heart attacks each year. We are pleased to provide the ACTCellerate platform in an effort to provide an alternative to heart transplantation for individuals with severely injured hearts, a treatment that is limited by the availability of donor hearts."
William M. Caldwell, IV, Chairman and CEO of ACTC, added, "We are excited about the implications this current grant has for cardiovascular disease and pleased to be working with academia to help find a solution."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
UC Disclaimer
The information stated above was prepared by Advanced Cell Technology, Inc., to report the outcome of their product and reflects solely the opinion of ACT. Nothing in this statement shall be construed to imply any support or endorsement of ACT, or any of its products, by The Regents of the University of California, its officers, agents and employees.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of Advanced Cell Technology, Inc. Alameda, California
We have audited the accompanying consolidated balance sheet of Advanced Cell Technology, Inc. as of December 31, 2006 and the related consolidated statements of operations, stockholders’ deficit, and cash flows for each of the years in the two-year period ended December 31, 2006. These financial statements are the responsibility of the company’s management. Our responsibility is to express an opinion on these financial statements based on our audits.
We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Advanced Cell Technology, Inc. as of December 31, 2006 and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2006 in conformity with accounting principles generally accepted in the United States of America.
As discussed in Note 11 to the consolidated financial statements, in 2006 the Company adopted statement of Financial Accounting Standards No. 123 (Revised 2004), Share-Based Payment.
The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the consolidated financial statements, the Company has minimal sources of revenue, incurred substantial net losses, has substantial monetary liabilities in excess of monetary assets and accumulated deficits as of December 31, 2006. These matters, among others, raise a substantial doubt about the Company’s ability to continue as a going concern. Management’s plans concerning these matters are described in Note 1. These consolidated financial statements do not included any adjustments relating to the recoverability and classification of recorded assets, or amounts and classification of liabilities that might be necessary in the event the Company cannot continue in existence.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell's Michael D. West, Ph.D., to Speak at 3rd Annual Stem Cell Research and Therapeutics Summit on ``Strategies for the Accelerated Development of Therapeutics from hES Cells''
Mar 23, 2007 08:33:10 (ET)
ALAMEDA, Calif., Mar 23, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Michael D. West, Ph.D., President and Chief Scientific Officer, will discuss "Strategies for the Accelerated Development of Therapeutics from hES Cells" at the 3rd Annual Stem Cell Research and Therapeutics Summit hosted by GTCbio today March 23, 2007, at 2:30 PM PT in California. The conference is being held at the San Diego Marriott La Jolla Conference Center and will run from March 22-23, 2007.
In his discussion, Dr. West will discuss the company's ACTCellerate technology and the heart muscle progenitor SK17 that is being studied under a recently funded CIRM grant.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the year ended December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
posted
Stem Cell Stocks Set To Soar TheStreet.com TV - Mon, Mar 26 - 4:00pm ET
you talkin about this one? My puter won't load it gotta wait till i get home.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Advanced Cell's Robert Lanza, M.D. Will Speak on 'Promise: The Future of Stem Cells' Wednesday, March 28, 2007 at 7:30 PM at Quinnipiac University in Hamden, CT, Presented by StemConn 2007
Last update: 3/28/2007 8:30:24 AMALAMEDA, Calif., Mar 28, 2007 (BUSINESS WIRE)
-- Advanced Cell Technology, Inc.'s (ACTC) Robert Lanza, M.D., VP of Research and Scientific Development, will participate in a panel discussion titled, "Promise: The Future of Stem Cell Research," March 28, 2007 at 7:30 PM, at Quinnipiac University in Hamden, CT.
The televised public forum, being presented by StemConn 2007, is for general audiences and focuses on the key issues that surround stem cell research. The panel discussion will be held in the Mancheski Executive Seminar Room, located in the Lender School of Business.
For more information regarding StemConn 2007 including a complete program guide of the two-day event being held March 27-28, 2007, log on to .
About Advanced Cell Technology, Inc. Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit .
Forward-Looking Statements Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the year ended December 31, 2006. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
posted
Advanced Cell's Robert Lanza, M.D. Will Speak on 'Promise: The Future of Stem Cells' Wednesday, March 28, 2007 at 7:30 PM at Quinnipiac University in Hamden, CT, Presented by StemConn 2007
Mar 28, 2007 08:30:24 (ET)
ALAMEDA, Calif., Mar 28, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc.'s (ACTC, Trade ) Robert Lanza, M.D., VP of Research and Scientific Development, will participate in a panel discussion titled, "Promise: The Future of Stem Cell Research," March 28, 2007 at 7:30 PM, at Quinnipiac University in Hamden, CT. The televised public forum, being presented by StemConn 2007, is for general audiences and focuses on the key issues that surround stem cell research. The panel discussion will be held in the Mancheski Executive Seminar Room, located in the Lender School of Business.
For more information regarding StemConn 2007 including a complete program guide of the two-day event being held March 27-28, 2007, log on to http://stemconn.org/program.htm .
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the Annual Report on Form 10-KSB for the year ended December 31, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Just having trouble lining these numbers up compared to the form 10 filed earlier (19 Mar)...
"Grant reimbursements for the twelve months ended December 31, 2006 and 2005 were approximately $369,000 and $742,000, respectively."
and...
"Other income/ (expense) for the twelve months ended December 31, 2006 and December 31, 2005 were approximately ($1,037,000) and $1,562,000, respectively"
the other numbers match.
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
Member Rated: posted March 28, 2007 10:38 AM -------------------------------------------------------------------------------- Fins are out too which could explain the dip. Takes money to make money.
posted
Advanced Cell Commends Massachusetts Governor Deval Patrick's Decision to Push to Reverse Stem Cell Research Restrictions
Apr 3, 2007 12:17:47 (ET)
ALAMEDA, Calif., Apr 03, 2007 (BUSINESS WIRE) -- Advanced Cell Technology, Inc. (ACTC, Trade ) commends Massachusetts Governor Deval Patrick's decision to reverse stem cell research restrictions imposed by his predecessor, Mitt Romney. Patrick told a roundtable of biotechnology officials at a meeting of the Life Science Council, "I believe that life sciences should be guided by science, not politics." Many in the scientific community contended that Romney's restrictions could have prevented them from using some stem cells. It was also widely asserted that the restrictions undercut a 2005 law that was approved by the state legislature over Romney's veto. Should Patrick successfully reverse the research restrictions, Massachusetts will join a growing number of states that have passed legislation or proposed initiatives to expand funding for embryonic stem cell research. These states include, but are not limited to, California, New York, New Jersey, Connecticut, Florida, and Missouri.
Commenting on the Governor's initiative, Martha Coakley, Attorney General of Massachusetts, recently stated, "I applaud the Governor for taking steps to reverse the regulations put into place by the Romney administration restricting stem cell research in Massachusetts. Through stem cell research, we have the opportunity to cure so many diseases and improve the lives of countless people, not only in Massachusetts, but throughout the country, and in fact, the world."
William M. Caldwell, IV, Chief Executive Officer and Chairman of Advanced Cell Technology, commented, "We could not be more pleased with Governor Patrick's decision to follow-through on his campaign promise to reform the restrictive nature of the stem cell research environment in the state of Massachusetts. We hope this serves as a catalyst for other state governments to move in the same direction, ultimately providing a platform for funding not only for research, but for developmental projects that already exist. The opportunity is at hand for the state to quickly emerge as a national leader in this area of research, by focusing the funding on the translation of the basic science into bedside therapies. Furthermore, we believe that the potential for lifting restrictions on and expanding funding for embryonic stem cell research will help Massachusetts keep biotechnology companies and jobs in the state, where we maintain one of our two principal research and development laboratories."
About Advanced Cell Technology, Inc.
Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com .
Forward-Looking Statements
Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2006.
Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.
SOURCE: Advanced Cell Technology, Inc.
The Investor Relations Group Investors: James Carbonara, Joseph Kessler 212-825-3210 or Media: Bill Douglass, 212-825-3210
-------------------- LIFE IS 10% HOW YOU MAKE IT AND 90% HOW YOU TAKE IT! Posts: 9276 | From: San Diego CA | Registered: Jul 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Thanks IMAKE I'm not a member there though. Gotta be another free site that can provide that info. Looks like my wireless keyboard really messed up my last post!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
posted
Last Trade: 0.7900 Trade Time: 10:58AM ET Change: 0.0400 (5.33%) Prev Close: 0.75 Open: 0.76 Bid: 0.7800 x 2500 Ask: 0.7900 x 2500 1y Target Est: 2.51 Day's Range: 0.7400 - 0.8100 52wk Range: 0.26 - 2.32 Volume: 757,649 Avg Vol (3m): 941,030 Market Cap: 37.31M P/E (ttm): N/A EPS (ttm): -0.64 Div & Yield: N/A (N/A)
I'll take that 1 yr taget anytime!!
-------------------- All post are my opinion. Do your own DD. Who's clicking your buy/sell button!? Posts: 7800 | From: Virginia | Registered: May 2006
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Big Grin]](biggrin.gif)
![[Razz]](tongue.gif)
Advanced Cell Technology hESC lines to be used in CIRM-Funded Study To Test Development of New Therapies For Heart Disease 
